Disease relevance of Benoral

• Fatal benorylate poisoning in a child with cystic fibrosis [1].
• The photodegradation of benorylate [4'-(acetamido)phenyl-2-acetoxybenzoate], a drug frequently used in rheumatoid arthritis therapy, has been examined under different sets of experimental conditions [2].
• Symptomatic response of osteoarthrosis to benorylate. A dose discrimination study [3].
• No serious side effect, attributable to benorylate was reported and it was concluded that the drug is satisfactory for the long term treatment of rheumatic diseases [4].
• In this two-week study, Benoral tablets, at a 4.5 g daily dosage were compared with a matching placebo in 20 patients suffering from sports injury [5].

High impact information on Benoral

• Hydrolysis of acetylsalicylate, benorylate, phenetsal, fluazifop butyl and paraoxon has been studied with freshly isolated rat hepatocytes maintained as a monolayer [6].
• Acetylsalicylate and paraoxon were the poorest substrates for hydrolysis whereas benorylate was hydrolysed one hundred times faster [6].
• Hepatotoxic metabolic activation of paracetamol and its derivatives phenacetin and benorilate: oxygenation or electron transfer [7]?
• 1. Benorylate (4-acetamido phenyl-O-acetylsalicylate) hydrolysis in vitro by human plasma and by human liver microsomes and cytosol has been investigated [8].
• 3. Benorylate was more actively hydrolysed by liver cytosol than microsomes and about 10 times faster than plasma [8].

Chemical compound and disease context of Benoral

• Fatal paracetamol poisoning from benorylate therapy in child with cystic fibrosis [9].
• Indomethacin and benorylate in osteoarthrosis of the hip [10].

Biological context of Benoral

• A two-week assessment of Benoral tablets was carried out in general practice in 171 patients with degenerative joint disease to see how symptomatic response related to selected presenting features of the disease [11].
• The bioavailability of benorylate in hot beverages [12].
• Simultaneous pharmacokinetics of benorylate in plasma and synovial fluid of patients with rheumatoid arthritis [13].

Anatomical context of Benoral

• Mitogen-induced proliferation of spleen lymphocytes was also inhibited in the treated mice; these inhibitions were negligible in the case of cells from acetylsalicylic acid-treated mice activated by concanavalin A and slight in cells from Benorilate-treated mice activated by bacterial lipopolysaccharide [14].
• The mean amniotic fluid unconjugated T for 49 patients carrying female fetuses of 41 pg. per milliliter (95 per cent CL: 11 TO 125) was fivefold lower than that for the male fetuses and all but three patients carrying female fetuses had amniotic fluid T levels of 90 pg. per milliliter or lower [15].
• The efficacy of a single pre-operative dose of benorylate (4 g) was determined in a double-blind, randomized, placebo-controlled parallel study in patients undergoing removal of a single impacted lower third molar [16].
• The passage of benorylate into the synovial fluid and tissue of rheumatoid patients [17].
• It is possible that part of the clinical effect of benorylate is due to its presence in the synovial tissue and that it has a direct effect in vivo on the synovial membrane [18].

Associations of Benoral with other chemical compounds

• Comparative metabolism of benorylate and an equivalent mixture of aspirin and paracetamol in neonate and adult rabbits [19].
• A double-blind study of benorylate and chlormezanone in musculoskeletal disease [20].
• Synovial fluid and plasma samples were obtained up to 9 hours after drug administration and assayed for their salicylate and benorylate content [13].
• In a double-blind, cross-over study of 90 patients with degenerative disease of the hip, knee, cervical or lumbar spine, and capsulitis of the shoulder the analgesic drug benorylate (either alone or in combination with chlormezanone, a muscle relaxant anxiolytic drug) favourably modified pain, stiffness, quality of sleep and ability to work [20].

Gene context of Benoral

• A long-term study of benorylate in patients with rheumatoid arthritis [21].

Analytical, diagnostic and therapeutic context of Benoral

• It is concluded from this study that a single dose of benorylate 4 g given immediately prior to the removal of an impacted lower third molar provides limited pain control during the postoperative period [16].
• This study compared benorylate suspension and placebo in a double-blind randomised cross-over design to investigate their analgesic effect in osteoarthritis of the hip and the knee [22].
• Studies measuring occult blood loss in the stools have shown that this is not a significant problem with benorylate and that the majority of patients lose no more blood than the controls [23].
• The 14C in the intestine was present as unchanged benorylate, as detected by thin-layer chromatography, suggesting that benorylate absorption was slow [24].
• Following oral administration of 4-acetamido-phenyl-2-acetoxybenzoate (carboxyl-14C) (benorylate) to rats, no gross differences were detected 7.5 h after administration with respect to the distribution of 14C in various tissues, including the upper sections of the small intestine [24].

References